Bluegrass Beacon: Drama of disruptive protests exacerbates testing woes

Ample evidence provided by the latest test scores assessing Kentucky’s academic performance during the 2018-19 school year suggests too many of our students struggled academically and that the drama and disruption caused by teachers’ illegal strikes and school shutdowns exacerbated the problems. The percentage of students in both Kentucky’s middle and high schools who demonstrated…

Bluegrass Institute commends progress toward increased KRS investment transparency

For Immediate Release: Tuesday, October 8, 2019 (FRANKFORT, Ky.) – The Bluegrass Institute Pension Reform Team issued the following statement in response to the Public Pension Oversight Board’s recent discussion regarding transparency of Kentucky Retirement Systems (KRS) investment fees, which included a presentation by State Auditor Mike Harmon.  The Bluegrass Institute has always been a…

Bluegrass Beacon – Lacking: Transparency and judicial good sense

A lack of transparency and judicial good sense provide this edition of “Liberty Boosters and Busters.” Liberty Booster: Kentucky Auditor Mike Harmon, who released an audit confirming a culture of secrecy continues to exist within the commonwealth’s two largest public-retirement systems more than two years after the General Assembly unanimously passed legislation requiring the major…

Prescription-drug policy: Remove obstacles keeping alternatives from reaching the market

We’ve focused in the first two posts of this three-part series addressing prescription-drug policy (here and here) on proposals in the United States Senate which offer solutions in search of problems, harm competition and allow brand-name drug companies to continue keep life-saving generics off the market for longer periods of time – all  with costly…

Prescription-drug policy: Don’t throw the bed out with bedpan

According to IQVIA, a health-care data firm, generic prescription drugs saved Kentucky $5.7 billion in 2017, $3.2 billion of which were savings reaped by the commonwealth’s Medicare and Medicaid programs. However, legislation (S. 64) being considered by the U.S. Senate would delay Kentucky patients access the more-affordable generic and biosimilar drugs being developed today. In…

Prescription-drug policy: Don’t give the FDA power over standards for biosimilar medicine

While Kentucky Senator and Majority Leader Mitch McConnell’s proposal to raise the legal age of purchasing tobacco has received a large share of attention regarding the suite of healthcare proposals currently being considered in the U.S. Senate, other issues affecting cost and access to health care – including for prescription drugs – must be carefully…